Brundin, Patrik

Parkinson disease

Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 5,415

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology

Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research

Cited by 4,476

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 1,845

Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology

Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 1,114

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells

Hansen, C., Angot, E., Bergström, A.-L., Steiner, J. A., Pieri, L., Paul, G., Outeiro, T. F., Melki, R., Kallunki, P., Fog, K., et al. (2011) · Journal of Clinical Investigation

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 842

Prion-like transmission of protein aggregates in neurodegenerative diseases

Brundin, P., Melki, R., & Kopito, R. (2010) · Nature Reviews Molecular Cell Biology

Prion Diseases and Protein MisfoldingAlzheimer's disease research and treatments

Cited by 778

Caspase signalling controls microglia activation and neurotoxicity

Burguillos, M. A., Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., et al. (2011) · Nature

Neuroinflammation and Neurodegeneration MechanismsInflammasome and immune disorders

Cited by 585

Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain

Li, W., Englund, E., Widner, H., Mattsson, B., van Westen, D., Lätt, J., Rehncrona, S., Brundin, P., Björklund, A., Lindvall, O., et al. (2016) · Proceedings of the National Academy of Sciences

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 313

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases

Espay, A. J., Vizcarra, J. A., Marsili, L., Lang, A. E., Simon, D. K., Merola, A., Josephs, K. A., Fasano, A., Morgante, F., Savica, R., et al. (2019) · Neurology

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 274

Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo

Angot, E., Steiner, J. A., Lema Tomé, C. M., Ekström, P., Mattsson, B., Björklund, A., & Brundin, P. (2012) · PLoS ONE

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 270

The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases

Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease

Olfactory and Sensory Function StudiesParkinson's Disease Mechanisms and Treatments

Cited by 257

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease

George, S., Rey, N. L., Tyson, T., Esquibel, C., Meyerdirk, L., Schulz, E., Pierce, S., Burmeister, A. R., Madaj, Z., Steiner, J. A., et al. (2019) · Molecular Neurodegeneration

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 229

Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity

Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences

Genetic Neurodegenerative DiseasesNeuroscience and Neuropharmacology Research

Cited by 228

Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term

Rey, N. L., George, S., Steiner, J. A., Madaj, Z., Luk, K. C., Trojanowski, J. Q., Lee, V. M.-Y., & Brundin, P. (2018) · Acta Neuropathologica

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 215

An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation

Brundin, L., Sellgren, C. M., Lim, C. K., Grit, J., Pålsson, E., Landén, M., Samuelsson, M., Lundgren, K., Brundin, P., Fuchs, D., et al. (2016) · Translational Psychiatry

Tryptophan and brain disordersSuicide and Self-Harm Studies

Cited by 195

The concept of alpha-synuclein as a prion-like protein: ten years after

Steiner, J. A., Quansah, E., & Brundin, P. (2018) · Cell and Tissue Research

Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

Cited by 183

Synaptic dysfunction in Huntington's disease: a new perspective

Smith, R., Brundin, P., & Li, J.-Y. (2005) · Cellular and Molecular Life Sciences

Genetic Neurodegenerative DiseasesNeuroscience and Neuropharmacology Research

Cited by 166

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial

Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Klingner, E., Caspell-Garcia, C., Lafontant, D.-E., Matthews, H., Wyse, R. K., Brundin, P., et al. (2021) · JAMA Neurology

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 149

Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease

Li, P., Killinger, B. A., Ensink, E., Beddows, I., Yilmaz, A., Lubben, N., Lamp, J., Schilthuis, M., Vega, I. E., Woltjer, R., et al. (2021) · Metabolites

Gut microbiota and healthParkinson's Disease Mechanisms and Treatments

Cited by 146

Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease

Björkqvist, M., Petersén, Å., Bacos, K., Isaacs, J., Norlén, P., Gil, J., Popovic, N., Sundler, F., Bates, G. P., Tabrizi, S. J., et al. (2006) · Human Molecular Genetics

Genetic Neurodegenerative DiseasesStress Responses and Cortisol

Cited by 138

Gut feelings about smoking and coffee in Parkinson's disease

Derkinderen, P., Shannon, K. M., & Brundin, P. (2014) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and Signaling

Cited by 115

Upregulation of α-synuclein following immune activation: Possible trigger of Parkinson's disease

Kasen, A., Houck, C., Burmeister, A. R., Sha, Q., Brundin, L., & Brundin, P. (2022) · Neurobiology of Disease

Parkinson's Disease Mechanisms and TreatmentsNeuroinflammation and Neurodegeneration Mechanisms

Cited by 78

Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease

Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites

Parkinson's Disease Mechanisms and TreatmentsMetabolomics and Mass Spectrometry Studies

Cited by 60

Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines

Ventorp, F., Bay-Richter, C., Nagendra, A. S., Janelidze, S., Matsson, V. S., Lipton, J., Nordström, U., Westrin, Å., Brundin, P., & Brundin, L. (2017) · Journal of Parkinson’s Disease

Neuroinflammation and Neurodegeneration MechanismsTryptophan and brain disorders

Cited by 56